Dr Reddy's Laboratories Limited today announced that it has launched Decitabine for injection, a therapeutic generic equivalent of Dacogen in the US yesterday following the approval by the United States Food and Drug Administration(USFDA).
The drug is used to treat Mylodysplastic Syndromes(MDS), a collection of blood-related medical conditions. Patients suffering from MDS often develop severe anemia and require frequent blood transfusions.
The Dacogen brand of this drug has US sales of around $260 million in 12 months ending July, 2013, the company said quoting the IMS Health statistics.